← All trials
NCT04548427
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 18, 2020
- Primary completion
- Nov 30, 2020
- Completion date
- Aug 31, 2021
- First posted
- Sep 14, 2020
- Last posted
- Sep 14, 2020
- Enrollment
- 280
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chong Kun Dang PharmaceuticalLead sponsor
- Pusan National UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.